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Summary
STAT3 regulates glucose homeostasis by suppressing the expression of gluconeogenic genes in the liver. The mechanism
by which hepatic STAT3 is regulated by nutritional or hormonal status has remained unknown, however. Here, we show that
an increase in the plasma insulin concentration, achieved either by glucose administration or by intravenous insulin infusion,
stimulates tyrosine phosphorylation of STAT3 in the liver. This effect of insulin was mediated by the hormone’s effects in the
brain, and the increase in hepatic IL-6 induced by the brain-insulin action is essential for the activation of STAT3. The inhi-
bition of hepatic glucose production and of expression of gluconeogenic genes induced by intracerebral ventricular insulin
infusion was impaired in mice with liver-specific STAT3 deficiency or in mice with IL-6 deficiency. These results thus indicate
that IL-6-STAT3 signaling in the liver contributes to insulin action in the brain, leading to the suppression of hepatic glucose
production.Introduction
An increase in glucose production in the liver is largely respon-
sible for the hyperglycemia in individuals with type 2 diabetes.
Insulin controls hepatic glucose production through regulation
of both glycogen metabolism and gluconeogenesis, with regula-
tion of the latter being achieved predominantly at the level of
expression of the genes for gluconeogenic enzymes including
those for phosphoenolpyruvate carboxykinase (PCK1) and for
glucose-6-phosphatase (G6PC; Radziuk and Pye, 2001). Insulin
suppresses the expression of such gluconeogenic genes
through activation of the insulin receptor (IR) and downstream
signaling by phosphoinositide 3-kinase (PI3K) in the liver (Mi-
chael et al., 2000; Miyake et al., 2002). The transcription factor
FoxO1 and the transcriptional coactivator CREB binding protein
appear to be involved in insulin regulation of gluconeogenic
gene expression in the liver (Nakae et al., 2002; Zhou et al.,
2004).
Apart from the direct activation of the insulin receptor signal-
ing in the liver, recent evidence has revealed that insulin action in
the brain also contributes to the suppression of hepatic glucoseCELL METABOLISM 3, 267–275, APRIL 2006 ª2006 ELSEVIER INC. Dproduction (Obici et al., 2002; Pocai et al., 2005a, 2005b). Intra-
cerebral ventricular (ICV) infusion of insulin results in the inhibi-
tion of glucose production as well as of the expression of gluco-
neogenic genes in the liver (Obici et al., 2002; Pocai et al.,
2005a). Moreover, ICV infusion of diazoxide, an opener of
ATP-sensitive potassium (KATP) channel, mimicked this effect
of insulin (Obici et al., 2002), and either ICV infusion of sulfonyl-
ureas, which selectively closes KATP channel, or the disruption of
the gene for SUR1, a component of KATP channel expressed in
the brain, prevented the insulin’s action in the brain (Pocai
et al., 2005b). These results suggest that the brain-insulin action
leading to the suppression of hepatic glucose production is
mediated by KATP channel though the molecular effector in
the liver responsible for this effect of insulin has remained un-
known.
We recently demonstrated that mice lacking STAT3 specifi-
cally in the liver displayed insulin resistance associated with
an increase in glucose production and the expression of gluco-
neogenic genes in the liver and forced expression of active
STAT3 suppressed gluconeogenic genes both in cultured hepa-
tocytes and in mouse liver (Inoue et al., 2004). Although theseOI 10.1016/j.cmet.2006.02.009 267
A R T I C L EFigure 1. Induction of STAT3 phosphorylation in the
liver by an increase in the circulating concentration of
insulin
A and B) Immunoblot analysis of the phosphorylation
(p) of STAT3 and of various signaling molecules in the
liver of wild-type mice at the indicated times either af-
ter feeding (A) or after intraperitoneal glucose admin-
istration (B) in animals deprived of food for 16 hr.
C and D) Phosphorylation of STAT3 (C and D) and of
Akt (C) either at 2 hr after the initiation of a hypergly-
cemic clamp with or without infusion of somatostatin
and insulin (C) or at the indicated times after the ini-
tiation of a euglycemic-hyperinsulinemic clamp (D).findings indicate the contribution of hepatic STAT3 in the control
of gluconeogenic genes in the liver, the mechanism by which the
transcription factor is regulated by nutritional or hormonal status
has remained unclear. In this study, we provide evidence that
STAT3 is activated by the insulin action in the brain and acts
as a hepatic effector of the brain-insulin action that leads to
the suppression of glucose production in the liver.
Results
Insulin induces hepatic STAT3 phosphorylation in vivo
We found that tyrosine phosphorylation of STAT3, which is es-
sential for the activity of this transcription factor, was induced
in the liver of mice in response to feeding. Tyrosine phosphory-
lation of STAT3 was thus not apparent in the liver of mice de-
prived of food for 16 hr but was manifest 3 hr after the onset
of subsequent feeding, before decreasing again to prefeeding
levels by 6 hr (Figure 1A), indicating that hepatic STAT3 signaling
is activated at postprandial states. The phosphorylation of
STAT3 in the liver was also transiently induced by intraperitoneal
administration of glucose, with maximal stimulation being ap-
parent after 2 to 3 hr (Figure 1B). Such feeding or glucose load-
ing also induced tyrosine phosphorylation of IR as well as serine
and threonine phosphorylation of Akt and FoxO1 (Figures 1A
and 1B), respectively, both of which are downstream mediators
of IR signaling (Nakae et al., 2002; Lizcano and Alessi, 2002). The
phosphorylation of IR and its downstream targets was more
rapid than was that of STAT3, however.
The circulating concentrations of both glucose and insulin are
increased after feeding. We thus investigated the contribution of
each of these factors to STAT3 phosphorylation in the liver. Dur-
ing a hyperglycemic clamp, in which the blood glucose concen-
tration was clamped at 350 to 400 mg/dl by continuous infusion268of glucose, phosphorylation of STAT3 was apparent in the liver
within 2 hr (Figure 1C). However, additional infusion of somato-
statin, which inhibits endogenous insulin secretion, markedly at-
tenuated the increase in STAT3 phosphorylation, whereas infu-
sion of insulin together with somatostatin prevented this effect of
the latter hormone. The pattern of changes in the level of Akt
phosphorylation in the liver was similar to that of the changes
in STAT3 phosphorylation (Figure 1C). Moreover, during a eugly-
cemic-hyperinsulinemic clamp, in which the blood glucose con-
centration was clamped at 100 to 120 mg/dl while insulin was
continuously infused, phosphorylation of STAT3 in the liver
was induced in a time-dependent manner (Figure 1D). These
results suggested that the postprandial increase in the circulat-
ing insulin concentration is responsible for the activation of
STAT3 in the liver.
Glucose intolerance in STAT3 and PDK1 deficiency
in the liver
The difference between the time courses of STAT3 and IR phos-
phorylation after glucose administration or feeding (Figures 1A
and 1B), together with the inability of insulin to induce STAT3
phosphorylation in cultured hepatocytes (Inoue et al., 2004),
suggested that insulin does not elicit STAT3 phosphorylation
in the liver through direct activation of hepatic IR-PI3K signaling
but rather that the circulating insulin level is coupled to hepatic
STAT3 signaling by an unidentified mechanism. 30-phosphoino-
sitide-dependent kinase-1 (PDK1) plays a key role in PI3K sig-
naling and is thought to be essential for the metabolic actions
of insulin (Lizcano and Alessi, 2002). Indeed, mice that lack
PDK1 specifically in the liver (L-Pdk1KO mice) exhibited hyper-
insulinemia (Table 1) as well as an exaggerated increase in
blood glucose concentration during a glucose-challenge testCELL METABOLISM : APRIL 2006
Hepatic STAT3/IL-6 and brain-insulin actionTable 1. Metabolic parameters and a liver function test of various knockout mice
BM BG Plasma Insulin ALT
n (g) (mg dl-1) (ng ml-1) (Karmen Unit)
C57/BL6 12 26.9 6 0.4 157.5 6 6.0 1.09 6 0.20 15.5 6 1.0
IL-6KO 8 26.1 6 0.5 149.4 6 6.0 1.32 6 0.19 12.8 6 0.4
Stat3-flox/flox 5 26.0 6 0.6 140.6 6 7.2 1.15 6 0.21 16.2 6 1.3
L-ST3KO 9 26.6 6 0.5 126.2 6 4.0 1.34 6 0.13 14.6 6 1.1
Pdk1-flox/flox 7 25.0 6 1.2 120.4 6 4.3 1.19 6 0.25 23.2 6 2.3
L-Pdk1KO 11 27.3 6 0.7 145.7 6 3.7 10.42 6 1.99a 21.9 6 1.3
Pdk1-flox/flox; Stat3-flox/flox 15 25.9 6 0.7 130.0 6 4.6 1.32 6 0.23 16.6 6 1.8
L-DKO 8 26.4 6 0.8 143.3 6 8.8 7.32 6 1.48b 25.1 6 2.9
Insr-flox/flox 5 27.1 6 0.6 128.6 6 5.3 3.72 6 0.71 16.0 6 3.9
NIRKO 6 28.5 6 1.2 139.3 6 5.8 5.50 6 1.44 15.4 6 2.3
BM, body mass; BG, blood glucose.
Statistically significant differences are indicated as follows:
a p < 0.05 versus Stat3-flox/flox, L-ST3KO, Pdk1-flox/flox, and Pdk1-flox/flox; Stat3-flox/flox.
b p < 0.05 versus L-ST3KO and Pdk1-flox/flox; Stat3-flox/flox.(Figure 2A). This latter characteristic was associated with a
higher level of expression of gluconeogenic genes including
Pck1 and G6pc in the liver compared with that apparent in con-
trol mice (Figure 2B). Although blood glucose concentrations
during a glucose-challenge test were similar between mice lack-
ing STAT3 specifically in the liver (L-ST3KO mice) and their con-
trol littermates (Figure 2A), additional disruption of Stat3 in the
liver of L-Pdk1KO mice resulted in a further deterioration of glu-
cose tolerance and increase in the expression of gluconeogenic
genes in the liver (Figures 2A and 2B). Insulin-induced inhibition
of hepatic glucose production as assessed with a euglycemic-
hyperinsulinemic clamp was attenuated in L-ST3KO mice (Fig-
ure 2C), consistent with a previous report (Inoue et al., 2004).
This parameter was more severely impaired in L-Pdk1KO mice
than in L-ST3KO mice and, to a further greater extent, in
L-DKO mice (Figure 2C). The additive effects of PDK1 and
STAT3 deficiency suggest that the STAT3 and PDK1 pathways
responsible for the suppression of glucose production in the
liver are regulated independently. The findings that STAT3 in-
hibits Pck1 and G6pc expression via a PI3K-independent man-
ner in cultured hepatocytes (Inoue et al., 2004) and that glucose
administration induced phosphorylation of STAT3 in the liver of
L-Pdk1KO mice (Figure 2D) were consistent with this notion.
Phosphorylation of hepatic STAT3 in L-Pdk1KO mice was
greater than that in control mice (Figure 2D). This observation fa-
vors our hypothesis that the circulating insulin concentration is
responsible for the phosphorylation of STAT3 in the liver given
that L-Pdk1KO mice exhibit hyperinsulinemia (Table 1). The gen-
eral appearance and the histology of the liver appeared normal
in L-ST3KO mice; L-Pdk1KO and L-DKO mice (data not shown)
and serum levels of alanine aminotransferase, a marker of liver
damage, were within normal range in these knockout mice
and their control littermates (Table 1).
STAT3 is a hepatic effector of brain-insulin action
Insulin action in the brain regulates a variety of biological activ-
ities, including glucose production in the liver (Bruning et al.,
2000; Obici et al., 2002; Schwartz and Porte, 2005). Phosphor-
ylation of hepatic STAT3 induced by glucose loading was atten-
uated in mice that lack the insulin receptor specifically in the
brain (NIRKO mice; Figure 3A), indicating that insulin action in
the brain contributes to postprandial activation of hepatic
STAT3. Injection of insulin into the cerebral ventricle of wild-CELL METABOLISM : APRIL 2006type mice resulted in phosphorylation of STAT3 in the liver in
a time-dependent manner (Figure 3B), demonstrating a direct
link between insulin action in the brain and hepatic STAT3 sig-
naling. The ICV infusion of insulin did not induce the phosphor-
ylation of IR (data not shown) or of Akt (Figure 3B) in the liver.
Consistent with previous observations (Obici et al., 2002; Pocai
et al., 2005a, 2005b), a pancreatic insulin clamp revealed that
ICV infusion of insulin induced inhibition both of glucose produc-
tion (Figure 3C) and of the expression of gluconeogenic genes
(Figure 3D) in the liver of control mice. In L-ST3KO mice, how-
ever, these effects of insulin were attenuated (Figures 3C and
3D), indicating that STAT3 is a hepatic effector of brain-insulin
action. Insulin-induced suppression of hepatic glucose produc-
tion as assessed with a euglycemic hyperinsulinemic clamp was
attenuated in NIRKO mice (Figure 3E), which is consistent with
the notion that the brain-insulin signaling plays a role in the sup-
pression of hepatic glucose production. Although female NIRKO
mice have been shown to exhibit obesity, body mass of male
NIRKO mice did not significantly differ from those of control
mice (Bruning et al., 2000). Indeed, body mass of NIRKO mice
used in the present study was not different from that of control
animals.
IL-6 mediates insulin-induced STAT3 phosphorylation
IL-6 activates STAT3 and inhibits the expression of gluconeo-
genic genes in cultured hepatocytes (Christ et al., 2000; Inoue
et al., 2004), and transplantation of a tumor that produces this
cytokine into mice resulted in inhibition of G6pc expression in
the liver (Metzger et al., 1997). We thus investigated whether
IL-6 is involved in phosphorylation of hepatic STAT3 induced
by insulin action in the brain. Administration of antibodies to
IL-6 prevented phosphorylation of STAT3 in the liver induced
by a bolus injection of IL-6 (Figure 4A), indicating that these an-
tibodies neutralize circulating IL-6 in mice. Administration of
these neutralizing antibodies to IL-6 also prevented the induc-
tion of STAT3 phosphorylation in the liver either by a euglyce-
mic-hyperinsulinemic clamp (Figure 4B) or by the ICV insulin
infusion (Figure 4C). Moreover, phosphorylation of STAT3 in
the liver induced by the ICV insulin infusion was inhibited in
mice that lack IL-6 (IL-6KO mice; Figure 4D). These results indi-
cate that IL-6 is essential for phosphorylation of hepatic STAT3
induced by the brain-insulin action. Inhibition of hepatic glu-
cose production in response to the ICV insulin infusion was269
A R T I C L EFigure 2. Additive effects of STAT3 and PDK1 defi-
ciency in the liver on glucose homeostasis
A and B) Blood glucose levels during (A) and hepatic
gluconeogenic gene expression at 3 hr after the initi-
ation of (B) a glucose tolerance test in L-ST3KO
L-Pdk1KO, L-DKO, and control mice. Data are
means 6 SEM (n = 4); *p < 0.05 (ANOVA).
C) Hepatic glucose production assessed with the
use of a euglycemic-hyperinsulinemic clamp in
L-ST3KO, L-Pdk1KO, L-DKO, and control mice.
The absolute values (left) and percent inhibition
(right) of hepatic glucose production are shown.
Data are means 6 SEM (n = 4); *p < 0.05 (ANOVA).
D) The level of STAT3 phosphorylation in the liver of
L-Pdk1KO, L-DKO, and control mice before and 3 hr
after intraperitoneal glucose administration was de-
termined by immunoblot analysis. The hepatic abun-
dance of STAT3 and PDK1 was also determined.attenuated in IL-6KO mice (Figure 4E), suggesting that IL-6 is in-
volved in the brain-insulin action leading to the hepatic glucose
production. Moreover, inhibition of hepatic glucose production
assessed by a euglycemic hyperinsulinemic clamp was also at-
tenuated in IL-6KO mice (Figure 4F), which is consistent with the
notion that IL-6 contributes to the suppression of hepatic glu-
cose production. Although IL-6KO mice have been shown to
develop age-related obesity, the animals younger than 6 months
old were not obese (Wallenius et al., 2002). Body mass of IL-6KO
mice used in this study (2 to 3 months old) did not differ from that
of control mice (Table 1), suggesting that the metabolic pheno-
types of these animals observed in the present study are not
likely attributable to secondary effects induced by obesity.270In response to intraperitoneal administration of lipopolysac-
charide (LPS), known to induce various cytokines in living ani-
mals, the mRNA abundance of IL-6 as assessed with RT-PCR
analysis was markedly increased in the liver of wild-type mice,
whereas this treatment did not induce the signal in the liver of
IL-6KO mice (Figure 5A). After the ICV insulin infusion, the
mRNA abundance of IL-6 in wild-type mice was two times
greater than that in mice after the ICV vehicle infusion, indicating
that insulin action in the brain stimulates IL-6 production in the
liver. In situ hybridization analysis revealed that spindle-shaped
IL-6 mRNA-positive cells scattered in the liver lobules were in-
duced in wild-type mice, but not in IL-6KO mice, in response
to LPS treatment (Figure 5B). The positive cells were locatedCELL METABOLISM : APRIL 2006
Hepatic STAT3/IL-6 and brain-insulin actionFigure 3. STAT3 is a hepatic effector of brain-insulin
action
A and B) Phosphorylation of STAT3 (A and B) and
Akt (B) in the liver either before and 3 hr after intraper-
itoneal glucose administration in NIRKO and control
Insr-flox/flox mice (A) or at the indicated times after
the initiation of ICV infusion of insulin (or vehicle) in
C57/BL6 mice (B). The abundance of IR in the hypo-
thalamus was also determined in (A).
C and D) Hepatic glucose production (C) and the ex-
pression of hepatic gluconeogenic genes (D) before
(C) and after (C and D) initiation of a pancreatic insu-
lin clamp performed together with ICV infusion of in-
sulin (or vehicle) in L-ST3KO and control Stat3-flox/
flox mice. The absolute values (left) and percent
inhibition (right) of hepatic glucose production are
shown (C).
E) The absolute values (left) and percent inhibition
(right) of hepatic glucose production assessed with
the use of a euglycemic-hyperinsulinemic clamp in
NIRKO mice and control Insr-flox/flox mice.
Data in (C), (D), and (E) are means6 SEM (n = 4); *p <
0.05 (ANOVA).adjacent to larger-sized cuboidal-shaped hepatocytes. In the
liver after the ICV insulin infusion in wild-type mice, similar spin-
dle-shaped IL-6 mRNA-positive cells were observed, though the
number and the signal intensity were smaller than those in the
liver of LPS-treated wild-type mice. Whereas the plasma con-
centration of IL-6 was below the detection limit (3 pg ml21) after
the ICV infusion of insulin or vehicle in wild-type mice, the
hepatic content of IL-6 after the ICV insulin infusion was higher
than that after the ICV vehicle infusion (3.07 6 0.96 versus
<0.94 pg per milligram of protein; means 6 SEM; n = 11 andCELL METABOLISM : APRIL 20066, respectively). These results together with a finding that phos-
phorylation of STAT3 was not detected in organs other than the
liver including skeletal muscle and adipose tissue after the ICV
infusion of insulin (data not shown) suggest that IL-6 acts as
a paracrine or autocrine factor.
Discussion
We previously showed that STAT3 regulates the expression of
gluconeogenic genes and thereby controls glucose production271
A R T I C L EFigure 4. IL-6 mediates suppression of hepatic glu-
cose production induced by insulin action in the brain
A) C57/BL6 mice were injected intraperitoneally first
with antibodies to IL-6 or control immunoglobulin G
(IgG) and then, after 5 days, with IL-6 (100 ng) or ve-
hicle. Phosphorylation of hepatic STAT3 was exam-
ined by immunoblot analysis 30 min after IL-6 injec-
tion.
B) Phosphorylation of STAT3 in the liver 2 hr after the
initiation of a euglycemic-hyperinsulinemic clamp (+)
or infusion of vehicle (2) in C57/BL6 mice injected in-
traperitoneally with neutralizing antibodies to IL-6 or
with control IgG.
C and D) Phosphorylation of STAT3 in the liver 3 hr
after the initiation of ICV infusion of insulin (or vehicle)
either in C57/BL6 mice that had been administered
antibodies to IL-6 or control IgG (C) or in IL-6KO
and C57/BL6 mice (Cont) (D).
E) Inhibition of hepatic glucose production after
a pancreatic insulin clamp with or without ICV infu-
sion of insulin in IL-6KO and C57/BL6 mice (Cont).
F) The absolute values (left) and percent inhibition
(right) of hepatic glucose production assessed with
the use of a euglycemic-hyperinsulinemic clamp in
IL-6KO and control C57/BL6 mice.
Data in (E) and (F) are means6 SEM (n = 4); *p < 0.05
(ANOVA).in the liver (Inoue et al., 2004). Our present study revealed that
hepatic STAT3 is activated by insulin action in the brain at post-
prandial states. This notion was supported by the inhibition of
hepatic STAT3 phosphorylation in NIRKO mice after glucose ad-
ministration and by the induction of STAT3 phosphorylation in
response to ICV infusion of insulin in normal mice. Moreover,
the suppression of glucose production induced by ICV infusion
of insulin was attenuated in mice lacking STAT3 specifically in
the liver. These results indicate that STAT3 is a hepatic effector
of the brain-insulin action that leads to the inhibition of hepatic
glucose production. Phosphorylation of STAT3 in the liver of
NIRKO mice was markedly but not completely inhibited after
glucose administration, suggesting that a mechanism indepen-
dent of the brain-insulin action also contributes to postprandial
activation of STAT3 in the liver. Such mechanisms remain to be
elucidated.
Consistent with a previous observation (Pocai et al., 2005a),
the suppression of glucose production in response to the ICV
infusion of insulin was associated with the decrease in the ex-
pression of geluconeogenic genes including Pck1 and G6pc.
In L-ST3KO mice, both of these effects of insulin were attenu-
ated, suggesting that the inadequate suppression of hepatic
glucose production in these animals is attributable, at least in
part, to the dysregulation of the gluconeogenic enzymes. Oka-
moto et al. (2005), however, reported that insulin-induced inhibi-
tion of hepatic glucose production was attenuated in mice
in which insulin signaling is impaired in hypothalamus but not
in the liver, whereas the expression of gluconeogenic genes in
the liver was not altered in these mice. It is thus possible that272insulin action in the brain affects hepatic glucose production
both through the regulation of the abundance of gluconeogenic
genes and thorough an unidentified mechanism independent of
the abundance of gluconeogenic genes.
The prevention of IL-6 signaling either by neutralizing anti-
bodies or by gene targeting almost completely abolished insu-
lin-induced phosphorylation of hepatic STAT3, and the ICV infu-
sion of insulin increased the expression of IL-6 in the liver. These
results suggest that the local production of IL-6 is important for
the phosphorylation of hepatic STAT3 induced by the brain-
insulin action. The suppression of hepatic glucose production
in response to the ICV insulin infusion was significantly, but
not completely, prevented in L-ST3KO mice and in IL-6KO
mice. These results suggest that, although the IL-6/STAT3 path-
way contributes to the insulin action in the brain, this pathway is
not the only pathway that mediates the insulin action in the brain.
The impairment of the insulin’s effect on hepatic glucose pro-
duction during a euglycemic hyperinsulinemic clamp in IL-6KO
mice is also consistent with the notion that IL-6 plays a role in
the regulation of hepatic glucose metabolism; however, we can-
not completely exclude the possibility that the lack of the cyto-
kine in whole body affects glucose metabolism through uniden-
tified secondary alterations. The distribution and the shape of
the cells positive for IL-6 mRNA were similar to those of hepatic
nonparenchymal cells such as Kupffer cells (Yamada et al.,
2003), which produces IL-6 in certain conditions (Gregory
et al., 1998). Further characteristics of the cells that produce
IL-6 in response to the brain-insulin action remain to be eluci-
dated. The circulating concentration of IL-6 has been shownCELL METABOLISM : APRIL 2006
Hepatic STAT3/IL-6 and brain-insulin actionFigure 5. Brain-insulin action increases the expres-
sion of IL-6 mRNA in the liver
A and B) Expression of IL-6 mRNA in the liver of C57/
BL6 mice (Cont) or IL-6KO mice 3 hr after intraperito-
neal injection of LPS (left panels) or 2 hr after the ini-
tiation of ICV infusion of insulin (or vehicle; right
panels) in the liver of C57/BL6 mice. The results of
RT-PCR analysis (A) and of in situ hybridization (B)
were shown. The data in the left panel of (A) are
means (n = 2) and in the right panel of (A) are means
6 SEM (n = 6 and 8 for vehicle-infused and insulin-
infused mice, respectively); *p < 0.05 (ANOVA).to be increased in obese or insulin-resistant individuals (Pickup
et al., 1997; Kern et al., 2001), and continuous intravenous infu-
sion of substantial amounts of IL-6 (500 ng/hr) results in insulin
resistance in mice (Kim et al., 2004), suggesting that this cyto-
kine contributes to the development of insulin resistance. How-
ever, the plasma concentration of IL-6 after continuous intrave-
nous infusion of IL-6 at a rate similar to that shown to induce
insulin resistance in mice (400 ng/kg/min) was markedly higher
than that after the ICV infusion of insulin (24506 384 pg/ml ver-
sus <3 pg/ml; means 6 SEM; n = 3). It is thus possible that IL-6
possesses bilateral functions in the regulation of glucose ho-
meostasis, a pathophysiological function and a normal physio-
logical function. It is likely that, although persistent and pro-
nounced systemic increases in the concentration of IL-6 might
trigger insulin resistance, transient and smaller local increases
in the amount of this cytokine contribute to normal glucose
homeostasis.CELL METABOLISM : APRIL 2006In conclusion, insulin proficiently regulates hepatic glucose
production by two different mechanisms, activation of PI3K sig-
naling through its direct effect in the liver and activation of IL-6/
STAT3 signaling thorough the effect in the brain. Each signaling
pathway is evoked in a different time course at postprandial
states and appears to be important to maintain normal glucose
homeostasis in the liver. Given that dysregulation of hepatic glu-
cose production is an important pathophysiological feature of
type 2 diabetes (Taylor, 1999), the mechanism uncovered in
this study may serve as a therapeutic target for this increasingly
prevalent condition.
Experimental procedures
Generation of mice with a floxed Pdk1 allele (Pdk1-flox mice)
The targeting vector was designed to delete exons 3 and 4 of the PDK1 gene.
A LoxP sequence was inserted into the Hind III site of intron 4, and a273
A R T I C L EpMC1-neo cassette (Shibata et al., 1996) flanked by LoxP sequences was
then inserted into the Nde I site of intron 2. A pMC1-DTA cassette (Shibata
et al., 1996) was incorporated at the 50 end of the region of homology. J1 em-
bryonic stem (ES) cells were transfected with the targeting vector and then
subjected to selection with G418. ES cell clones that had undergone homol-
ogous recombination with the targeting vector were identified by Southern
blot analysis. The LoxP-flanked neo cassette was removed by transient
transfection of the cells with a plasmid encoding Cre recombinase. Chimeric
mice were obtained by injecting J1 cells that had undergone homologous re-
combination and removal of the neo cassette into C57BL/6 blastocysts. Male
chimeras were then mated with C57BL/6 females to obtain mice with a floxed
Pdk1 allele.
Other animals
C57/BL6 mice were studied unless indicated otherwise. All genetically engi-
neered and C57/BL6 mice were male and 2 to 3 months of age. We gener-
ated IL-6KO mice by intercrossing Il-6+/2 animals with a genetic background
of C57/BL6 (Jackson Laboratory); C57/BL6 mice were used as controls. We
generated NIRKO mice, which are homozygous for a floxed allele of the IR
gene (Insr) and harbor a transgene for Cre recombinase under the control
of the Nestin gene promoter, as described (Bruning et al., 2000). We gener-
ated L-ST3KO mice, L-Pdk1KO mice, and L-DKO mice, which harbor a trans-
gene for Cre recombinase under the control of the albumin gene promoter
and are homozygous for a floxed allele of Stat3, Pdk1, or both Pdk1 and
Stat3, respectively, by crossing Alb-Cre mice (Yakar et al., 1999) with
Stat3-flox mice (Takeda et al., 1998), Pdk1-flox mice, and Stat3-flox;Pdk1-
flox mice, respectively. We used Insr-flox/flox littermates (for NIRKO mice),
Stat3-flox/flox littermates (for L-ST3KO mice), and Stat3-flox/flox;Pdk1-
flox/flox littermates (for L-Pdk1KO and L-DKO mice) as controls. Although
mice with liver-specific deficiency of PDK1 were previously shown to develop
a severe condition characterized by prominent edema and premature death
(Mora et al., 2005), the L-Pdk1KO mice generated in the present study ap-
peared normal, with the exception of glucose intolerance, until at least 6
months of age. The metabolic phenotypes of L-Pdk1KO and L-DKO mice
will be described elsewhere. The study was approved by the animal experi-
mentation committee of Kobe University Graduate School of Medicine.
Immunoblot analysis of STAT3 phosphorylation and of other
signaling molecules
The effects of feeding or glucose administration on STAT3 phosphorylation in
the liver were investigated in mice that had been deprived of food for 16 hr.
The animals were supplied with normal chow or injected intraperitoneally
with glucose (4 g/kg), and liver homogenates prepared at the indicated times
thereafter were subjected to immunoblot analysis.
Infusion of insulin (ICV), measurement of hepatic IL-6 content,
and neutralizing antibodies to IL-6
Insulin (porcine, Sigma-Aldrich) dissolved in artificial cerebroventricular fluid
was infused at a rate of 30 ng/kg/hr through an ICV catheter that had been
implanted into the third cerebral ventricle 7 to 10 days previously, as de-
scribed (Asakawa et al., 2001). Homogenates of mouse liver prepared 3 hr
after the initiation of ICV infusion of insulin were centrifuged to remove debris,
and the resulting supernatants were analyzed with an enzyme-linked immu-
nosorbent assay kit for mouse IL-6 (BioSource International). Liver extracts of
IL-6KO mice supplemented with various amounts of mouse recombinant IL-6
were used as an assay standard. Neutralizing antibodies to IL-6 (MP5-20F3,
R&D Systems) were injected intraperitoneally (0.1 mg per mouse) and their
effects were evaluated 3 to 5 days later.
Glucose tolerance test and clamp analyses
A glucose tolerance test (2 g/kg of glucose loaded intraperitoneally) and a
euglycemic-hyperinsulinemic clamp, in which blood glucose concentration
was clamped at 100 to 120 mg/dl while insulin (2.5 mU/kg/min) was infused
continuously, were performed as described (Inoue et al., 2004) in mice de-
prived of food for 16 hr; hepatic glucose production during the clamp was
also measured as described (Ren et al., 1995). Percent inhibition of hepatic
glucose production was determined by dividing the difference between the
hepatic glucose production at the basal state and that at the clamp state by
that at the basal state. A hyperglycemic clamp, in which blood glucose con-
centration was clamped at 350 to 400 mg/dl by continuous intravenous infu-
sion of glucose at a variable rate, was performed, either together with or with-274out intravenous injection of somatostatin (3 mg/kg/min) or insulin (2.5 mU/kg/
min), in mice that had been deprived of food for 16 hr. A pancreatic insulin
clamp was performed with ICV insulin infusion essentially as described (Obici
et al., 2002; Pocai et al., 2005a) with the following modifications: we implanted
an intravenous catheter into the cervical vein and, 3 days later, introduced an
ICV catheter into the third ventricle. The clamp analysis was performed 7 to 10
days after implantation of the ICV catheter and after the mice had been
deprived of food for 6 hr. Continuous ICV infusion of insulin was initiated at
time 0, and intravenous priming with [3-3H]glucose at a rate of 0.4 mCi/min
was started after 1 hr. At 3 hr, the pancreatic insulin clamp, consisting of intra-
venous infusion of insulin (0.3 mU/kg/min), somatostatin (3 mg/kg/min), and
glucose, was begun and was maintained for 2 hr. The rate of glucose infusion
was adjusted to maintain a blood glucose concentration of 100 to 120 mg/dl.
Hepatic glucose production during the pancreatic insulin clamp was deter-
mined as described (Obici et al., 2002; Pocai et al., 2005a).
Hepatic gene expression
Hepatic gene expression 3 hr after intraperitoneal glucose administration
(4 g/kg) or at the end of a pancreatic insulin clamp with or without ICV insulin
infusion was evaluated by reverse transcription and polymerase chain reac-
tion (RT-PCR) analysis, with 36B4 mRNA as the invariant control, as de-
scribed (Miyake et al., 2002). The primers for G6pc were 50-AGCCTCCGGAA
GTATCTCA-30 and 50-TCCACCCCTAGCCCTTTTAGTAG-30, for IL-6were 50-
CCACGGCCTTCCCTACTTC-30 and 50-TGGGAGTGGTATCCTCTGTGAA-30,
and those forPck1 and 36B4were as described (Miyake et al., 2002; Teshiga-
wara et al., 2005).
In situ hybridization
The livers was postfixed for 24 hr at 4ºC and placed in 0.1 M phosphate buffer
(pH 7.4) with 20% sucrose for 48 hr. Antisense probes to mouse IL-6 cDNA
(1-793) was labeled with digoxigenin-UTP following standard protocols of
cRNA synthesis. Liver sections (40 mm thick) were made by cryostat and pro-
cessed for in situ hybridization as described previously (Shigeyoshi et al.,
1997). Sections were processed for immunocytochemistry with the nucleic
acid detection kit (Boehringer Mannheim, Germany) and visualized blue
with nitroblue tetrazolium salt for 6 hr. Sense probes yielded no specific hy-
bridization signals in the liver sections.
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